For decades, LDL cholesterol was the near-exclusive target of cardiovascular prevention — but a growing body of evidence suggests that single-biomarker thinking leaves millions of high-risk adults inadequately protected. A clinical review in Cardiology and Therapy synthesizes how ASCVD risk stratification and lipid-lowering treatment are being fundamentally restructured, with implications for anyone managing long-term heart health.
The review identifies a meaningful shift in risk modeling: rather than relying solely on 10-year event probability, newer frameworks incorporate lifetime cardiovascular risk alongside genetic predisposition and comorbid risk-enhancing conditions. Three additional tools have moved from specialist to primary care relevance — lipoprotein(a) [Lp(a)], apolipoprotein B (ApoB), and coronary artery calcium (CAC) scoring. Together, these metrics help reclassify patients in borderline risk zones who might otherwise be undertreated or overtreated with statins. The review also highlights that current ACC/AHA and ESC/EAS guideline updates now formally endorse earlier intensification of therapy and the routine addition of non-statin agents — including PCSK9 inhibitors and newer ezetimibe combinations — rather than reserving them for statin-refractory cases. On the near horizon: polygenic risk scores and RNA-based therapies (such as inclisiran, a small interfering RNA targeting PCSK9) that may enable highly individualized intervention.
This synthesis is clinically valuable precisely because it maps the distance between guideline recommendations and typical primary care practice. Lp(a) remains significantly underordered despite being a genetically fixed, causally implicated cardiovascular risk factor. ApoB captures atherogenic particle burden more completely than LDL-C, yet adoption outside lipidology clinics is slow. The review's framing of RNA therapeutics as near-term rather than speculative is also noteworthy — inclisiran already holds regulatory approval in multiple jurisdictions. Key limitations: this is a narrative clinical review, not a meta-analysis or trial, so its conclusions reflect expert synthesis rather than new primary data. It functions best as a framework document for practitioners rather than a source of novel causal evidence. Still, for health-conscious adults and their clinicians, the core message is paradigm-relevant: standard LDL testing alone may no longer constitute adequate cardiovascular risk assessment.